Novo Nordisk A/S (NYSE:NVO) Upgraded by Morgan Stanley to “Equal Weight” Rating

Morgan Stanley upgraded shares of Novo Nordisk A/S (NYSE:NVO) from an underweight rating to an equal weight rating in a report published on Tuesday, Marketbeat reports. The brokerage currently has $40.00 price objective on the stock.

A number of other research analysts have also recently issued reports on the stock. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Novo Nordisk A/S in a report on Tuesday, February 24th. Jefferies Financial Group raised Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a report on Thursday, February 12th. Zacks Research lowered Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a report on Monday, February 9th. Nordea Equity Research cut Novo Nordisk A/S to a “hold” rating in a research report on Tuesday, February 24th. Finally, Citigroup started coverage on Novo Nordisk A/S in a research report on Tuesday, January 27th. They issued a “neutral” rating for the company. Five equities research analysts have rated the stock with a Buy rating, seventeen have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Novo Nordisk A/S has a consensus rating of “Hold” and a consensus price target of $53.93.

Novo Nordisk A/S Trading Down 2.9%

Shares of Novo Nordisk A/S stock opened at $36.68 on Tuesday. The stock has a market capitalization of $163.78 billion, a PE ratio of 10.57 and a beta of 0.73. Novo Nordisk A/S has a 52 week low of $35.85 and a 52 week high of $91.90. The stock has a 50 day moving average price of $52.24 and a two-hundred day moving average price of $52.68. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.57 and a current ratio of 0.80.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.90 by $0.11. The company had revenue of $12.43 billion for the quarter, compared to analysts’ expectations of $11.97 billion. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%. As a group, equities analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The firm also recently announced a dividend, which will be paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th will be paid a dividend of $1.2751 per share. This represents a dividend yield of 541.0%. The ex-dividend date is Monday, March 30th. Novo Nordisk A/S’s payout ratio is presently 23.63%.

Institutional Trading of Novo Nordisk A/S

Large investors have recently added to or reduced their stakes in the stock. Martin Capital Partners LLC grew its holdings in Novo Nordisk A/S by 53.8% during the 3rd quarter. Martin Capital Partners LLC now owns 117,577 shares of the company’s stock valued at $6,524,000 after buying an additional 41,129 shares in the last quarter. Clifford Swan Investment Counsel LLC boosted its position in shares of Novo Nordisk A/S by 13.7% in the third quarter. Clifford Swan Investment Counsel LLC now owns 311,168 shares of the company’s stock valued at $17,267,000 after acquiring an additional 37,453 shares during the period. Markel Group Inc. grew its stake in Novo Nordisk A/S by 4.9% during the third quarter. Markel Group Inc. now owns 2,368,649 shares of the company’s stock valued at $131,436,000 after acquiring an additional 110,061 shares in the last quarter. Cantor Fitzgerald Investment Advisors L.P. bought a new stake in Novo Nordisk A/S during the 3rd quarter worth approximately $1,294,000. Finally, WCM Investment Management LLC lifted its stake in Novo Nordisk A/S by 3.7% in the 3rd quarter. WCM Investment Management LLC now owns 2,732,182 shares of the company’s stock worth $151,636,000 after purchasing an additional 97,477 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Large Ireland manufacturing investments to defend market share and expand oral GLP‑1 capacity — boosts production flexibility and long‑term revenue defense. Novo Nordisk to invest $506 million in Ireland plant expansion
• Positive Sentiment: Major facility upgrade announced in Athlone (≈€432m) to add tabletting capacity for oral GLP‑1s, underlining commitment to scaling production outside the U.S. Novo Nordisk announces more than 400 million euro expansion in its manufacturing facility in Athlone, Ireland
• Positive Sentiment: Share repurchase program underway (part of up to DKK 15bn plan) — supports EPS and signals capital-return priority amid near‑term headwinds. Novo Nordisk A/S – share repurchase programme
• Positive Sentiment: Morgan Stanley upgraded NVO to Equal‑weight, saying the recent sell‑off better prices mid‑term risks and setting a $40 target — a modest analyst tailwind. Morgan Stanley upgrades Novo Nordisk, says risks better priced after sell-off
• Neutral Sentiment: Goldman Sachs reaffirmed a neutral rating but cut its price target, reflecting mixed views on near‑term margin/volume pressures vs. strategic moves. (Coverage note)
• Negative Sentiment: FDA ordered Novo to stop a consumer Ozempic ad for being false or misleading — raises regulatory risk, potential ad pullbacks and reputational concerns around product claims. US FDA warns Novo for second time about misleading Ozempic advertising
• Negative Sentiment: Investor class‑action investigation announced (Pomerantz) — could increase legal/settlement risk and add near‑term selling pressure. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S – NVO
• Negative Sentiment: Planned US list‑price cut for Wegovy (halved in 2027) — directly pressure on revenue and pricing power in the U.S. obesity market. Novo Nordisk to halve US list price of Wegovy in 2027
• Negative Sentiment: Generic/competitor threats: Aspen expects Canadian approval for a generic Ozempic formulation this year, which could erode market share outside the U.S. Aspen expects Canada nod for generic Ozempic this year
• Negative Sentiment: Competitive pressure rising — Roche is targeting double‑digit share in weight‑loss and Eli Lilly’s recent head‑to‑head clinical wins have intensified investor concern about GLP‑1 market share. Roche targets double-digit market share in weight loss, aims to catch up with Novo Nordisk, Handelsblatt reports

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.